a transcription factor that plays major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Heterodimers between E2A and tissue-specific basic helix-loop-helix (bHLH) Dimers bind DNA on E-box motifs: 5'- CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Deletions in E2A have been observed in a subset of pre-B-cell acute lymphoblastic leukemia (B-ALL) cases. Two alternatively spliced human isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: Cell development/differentiation; Transcription factor; DNA-binding; Oncoprotein
Molecular Function: bHLH transcription factor binding; chromatin binding; DNA binding; mitogen-activated protein kinase kinase kinase binding; PDZ domain binding; protein binding; protein heterodimerization activity; protein homodimerization activity; sequence-specific DNA binding; transcription coactivator activity; transcription factor activity; transcription factor binding
Biological Process: B cell lineage commitment; cell development; gastrulation; immunoglobulin V(D)J recombination; lymphocyte differentiation; natural killer cell differentiation; negative regulation of transcription from RNA polymerase II promoter; Peyer's patch development; positive regulation of B cell proliferation; positive regulation of cell cycle; positive regulation of neuron differentiation; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein stabilization; regulation of transcription from RNA polymerase II promoter; regulation of transcription, DNA-dependent; response to drug; response to lipopolysaccharide; T cell differentiation in the thymus; transcription, DNA-dependent
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.